​
​

Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PCVX Stock Forecast

Vaxcyte stock forecast is as follows: an average price target of $124.00 (represents a 40.29% upside from PCVX’s last price of $88.39) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

PCVX Price Target

The average price target for Vaxcyte (PCVX) is $124.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $163.00 to $58.00. This represents a potential 40.29% upside from PCVX's last price of $88.39.

PCVX Analyst Ratings

Buy

According to 9 Wall Street analysts, Vaxcyte's rating consensus is 'Buy'. The analyst rating breakdown for PCVX stock is 0 'Strong Buy' (0.00%), 9 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Vaxcyte Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Roger SongJefferies$146.00$106.7336.79%65.18%
Nov 06, 2024David RisingerLeerink Partners$135.00$106.7326.48%52.73%
Sep 10, 2024Salim SyedMizuho Securities$163.00$115.2841.39%84.41%
Sep 04, 2024Jason GerberryBank of America Securities$140.00$110.1527.10%58.39%
Sep 03, 2024David RisingerLeerink Partners$153.00$112.0436.56%73.10%
Sep 03, 2024Tom ShraderBTIG$160.00$110.1545.26%81.02%
Sep 03, 2024Roger SongJefferies$129.00$111.1316.09%45.94%
Sep 03, 2024Salim SyedMizuho Securities$113.00$111.081.72%27.84%
Aug 07, 2024Tom ShraderBTIG$98.00$70.5238.97%10.87%
Jan 03, 2023-Needham$58.00$47.9520.96%-34.38%
Row per page
Go to

The latest Vaxcyte stock forecast, released on Nov 06, 2024 by Roger Song from Jefferies, set a price target of $146.00, which represents a 36.79% increase from the stock price at the time of the forecast ($106.73), and a 65.18% increase from PCVX last price ($88.39).

Vaxcyte Price Target by Period

1M3M12M
# Anlaysts289
Avg Price Target$140.50$142.38$137.44
Last Closing Price$88.39$88.39$88.39
Upside/Downside58.95%61.08%55.49%

In the current month, the average price target of Vaxcyte stock is $140.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 58.95% increase as opposed to Vaxcyte's last price of $88.39. This month's average price target is down -1.32% compared to last quarter, and up 2.23% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024Leerink PartnersOutperformOutperformHold
Sep 04, 2024GuggenheimBuyBuyHold
Sep 03, 2024Cowen & Co.BuyBuyHold
Sep 03, 2024NeedhamBuyBuyHold
Sep 03, 2024BTIGBuyBuyHold
Sep 03, 2024JefferiesBuyBuyHold
Aug 07, 2024BTIGBuyBuyHold
Mar 12, 2024Morgan StanleyBuyBuyHold
Mar 12, 2024WedbushBuyBuyHold
Jan 03, 2023NeedhamBuyBuyHold
Row per page
Go to

Vaxcyte's last stock rating was published by Leerink Partners on Nov 06, 2024. The company gave PCVX a "Outperform" rating, the same as its previous rate.

Vaxcyte Financial Forecast

Vaxcyte Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
Revenue--------
Avg Forecast-------$166.67K
High Forecast-------$166.67K
Low Forecast-------$166.67K
# Analysts-------1
Surprise %--------

Vaxcyte's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PCVX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Vaxcyte EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
EBITDA-------$-19.96M
Avg Forecast-------$-12.81M
High Forecast-------$-10.24M
Low Forecast-------$-15.37M
Surprise %-------1.56%

undefined analysts predict PCVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vaxcyte's previous annual EBITDA (undefined) of $NaN.

Vaxcyte Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
Net Income-------$-20.32M
Avg Forecast$-141.63M$-137.92M$-134.21M$-133.59M$-138.26M$-136.16M$-114.39M$-13.12M
High Forecast$-141.63M$-137.92M$-134.21M$-133.59M$-95.32M$-136.16M$-114.39M$-10.50M
Low Forecast$-141.63M$-137.92M$-134.21M$-133.59M$-227.29M$-136.16M$-114.39M$-15.74M
Surprise %-------1.55%

Vaxcyte's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PCVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Vaxcyte SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
SG&A-------$2.01M
Avg Forecast--------
High Forecast--------
Low Forecast--------
Surprise %--------

Vaxcyte's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PCVX last annual SG&A of $2.01M (Jun 20).

Vaxcyte EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
EPS-------$-1.72
Avg Forecast$-1.15$-1.11$-1.08$-1.08$-1.12$-1.10$-0.98$-1.27
High Forecast$-1.15$-1.11$-1.08$-1.08$-0.77$-1.10$-0.98$-1.27
Low Forecast$-1.15$-1.11$-1.08$-1.08$-1.84$-1.10$-0.98$-1.27
Surprise %-------1.36%

According to undefined Wall Street analysts, Vaxcyte's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PCVX previous annual EPS of $NaN (undefined).

Vaxcyte Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$1.73$33.861857.23%Buy
STROSutro Biopharma$2.53$11.14340.32%Buy
LRMRLarimar Therapeutics$6.13$20.33231.65%Buy
APLSApellis Pharmaceuticals$27.75$74.50168.47%Buy
IMCRImmunocore$32.12$70.75120.27%Buy
SNDXSyndax Pharmaceuticals$15.60$34.30119.87%Buy
LEGNLegend Biotech$39.75$82.69108.03%Buy
VRDNViridian Therapeutics$19.62$37.9293.27%Buy
MRUSMerus$44.36$76.6772.84%Buy
LQDALiquidia$10.15$17.1769.16%Buy
BMRNBioMarin Pharmaceutical$63.45$101.7060.28%Buy
AKROAkero Therapeutics$31.20$46.0047.44%Buy
PCVXVaxcyte$88.39$124.0040.29%Buy
TECHBio-Techne$71.05$91.6929.05%Buy
DICEDICE Therapeutics$47.55$60.0026.18%Buy
NUVLNuvalent$92.73$111.5720.32%Buy
TVTXTravere Therapeutics$18.26$21.7519.11%Buy
ACLXArcellx$87.22$83.00-4.84%Buy

PCVX Forecast FAQ

Is Vaxcyte a good buy?

Yes, according to 9 Wall Street analysts, Vaxcyte (PCVX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 100.00% of PCVX's total ratings.

What is PCVX's price target?

Vaxcyte (PCVX) average price target is $124 with a range of $58 to $163, implying a 40.29% from its last price of $88.39. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Vaxcyte stock go up soon?

According to Wall Street analysts' prediction for PCVX stock, the company can go up by 40.29% (from the last price of $88.39 to the average price target of $124), up by 84.41% based on the highest stock price target, and down by -34.38% based on the lowest stock price target.

Can Vaxcyte stock reach $130?

PCVX's highest twelve months analyst stock price target of $163 supports the claim that Vaxcyte can reach $130 in the near future.

What is Vaxcyte's current price target trend?

2 Wall Street analysts forecast a $140.5 price target for Vaxcyte (PCVX) this month, up 58.95% from its last price of $88.39. Compared to the last 3 and 12 months, the average price target increased by 61.08% and increased by 55.49%, respectively.

What are Vaxcyte's analysts' financial forecasts?

Vaxcyte's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-389M (high $-346M, low $-478M), average SG&A $0 (high $0, low $0), and average EPS is $-3.194 (high $-2.847, low $-3.914). PCVX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-547M (high $-547M, low $-547M), average SG&A $0 (high $0, low $0), and average EPS is $-4.425 (high $-4.425, low $-4.425).